Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04629508 · ClinicalTrials.gov registry record · Phase 2
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04629508 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 4 participants.
The verdict
NCT04629508, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
Interventions
- DRUG itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2023-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04629508
The ClinicalTrials.gov registry entry for NCT04629508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which itacitinib is the first listed.
NCT04629508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04629508 about?
NCT04629508 is a clinical study titled "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)". This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
What is the current status of trial NCT04629508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-07-12. Estimated completion is 2023-08-24.
What interventions are being tested in trial NCT04629508?
The interventions under investigation include: itacitinib (DRUG).
Who is sponsoring clinical trial NCT04629508?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.